関連する実験動画
Updated: May 10, 2026

11:33
Isolation and Kv Channel Recordings in Murine Atrial and Ventricular Cardiomyocytes
Published on: March 12, 2013
アルファ2サブユニットに関連したAMPK活性の増加とPRKAG2心筋病変
Ferhaan Ahmad1, Michael Arad, Nicolas Musi
1Department of Genetics, Harvard Medical School, Howard Hughes Medical Institute, Boston, MA, USA.
Circulation
|November 9, 2005
まとめ
PRKAG2の変異は,α2-AMPKを活性化し,グリコゲンの蓄積につながり,心筋病を引き起こす. マウスのアルファ2-AMPKを阻害することで,心臓および伝導異常が逆転し,アルファ2が重要な媒介体であると特定しました.
科学分野:
- バイオケミストリー バイオケミストリー
- 心臓病学 心臓病学
- 遺伝学 遺伝学とは
背景:
- AMP活性化タンパク質キナーゼ (AMPK) 調節性ガンマ2サブユニット (PRKAG2) 変異は,ヒトの心筋疾患に関連しています.
- この状態には,心筋縮,前刺激,およびグリコゲン堆積が含まれます.
- PRKAG2心筋病は,変異性PRKAG2 N488I (TGgamma2N488I) を過剰発現したマウスでモデル化されています.
研究 の 目的:
- PRKAG2心筋病変におけるアルファ1およびアルファ2AMPKサブユニットイソフォームの役割を調査する.
- アルファ2関連AMPKの活性を阻害することで,疾患の表型を改善できるかどうかを判断する.
主な方法:
- アルファ2-AMPKの活性を選択的に抑制するために,支配的陰性アルファ2サブユニット (TGalpha2DN) を過剰発現するトランスジェニックマウスを利用しました.
- 生成された化合物-ヘテロジゴスTGgamma2N488I/TGalpha2DNマウス.
- 評価されたEKG,心臓機能,形態学,運動能力,心臓のグリコゲン含有量.
主要な成果:
- 複合性ヘテロジゴスマウスは,TGgamma2N488Iマウスと比較して,α2-AMPKの活性が低下した.
- TGalpha2DNトランスゲンは,ECG,心臓機能,形質,運動能力を部分的にまたは完全に正常化させました.
- TGgamma2N488I心臓は,通常の休息時のエネルギーホルファットを示し,運動中に貯蔵されたグリコゲンを利用しました.
結論:
- PRKAG2 N488I変異は,AMPKを不適切に活性化し,グリコゲンの蓄積と伝導系疾患を引き起こす.
- 蓄積されたグリコゲンはエネルギー源として機能し,運動中に収縮準備力を保ちます.
- アルファ1ではなくアルファ2サブユニットを含むAMPK複合体は,PRKAG2変異効果の主な媒介体である.
関連する概念動画
mTOR Signaling and Cancer Progression
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
PI3K/mTOR/AKT Signaling Pathway
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a rapamycin-insensitive companion...
GPCRs Regulate Adenylyl Cylase Activity
Some GPCRs transmit signals through adenylyl cyclase (AC), a transmembrane enzyme. AC helps synthesize second messenger cyclic adenosine monophosphate (cAMP). AC catalyzes cyclization reaction and converts ATP to cAMP by releasing a pyrophosphate. The pyrophosphate is further hydrolyzed to phosphate by the enzyme pyrophosphatase, which drives cAMP synthesis to completion. However, cAMP is rapidly degraded to 5′ AMP by the enzymes phosphodiesterase (PDE), preventing overstimulation of cells.
Two...
Two...
cAMP-dependent Protein Kinase Pathways
Cyclic Adenosine Monophosphate (cAMP) is an essential second messenger that activates protein kinase A (PKA) and regulates various biological processes. A single epinephrine molecule binds to GPCR and activates several heterotrimeric G proteins, each stimulating multiple adenylyl cyclase, amplifying the signal, and synthesizing large numbers of cAMP molecules. Small changes in cAMP concentration affect PKA activity. The binding of four cAMP molecules induces a conformational change in PKA,...
Cardiomyopathy II: Dilated Cardiomyopathy
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...

